Latest News
The U.S. Food and Drug Administration Approves Zanubrutinib for Marginal Zone Lymphoma
On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval of zanubrutinib (BRUKINSA, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
The drug had previously been approved for the treatment of mantle cell lymphoma (MCL) in adults patients who have received at least one prior therapy and adult patients with Waldenstrӧm macroglobulinemia (WM).
“The approval of zanubrutinib offers patients with relapsed and refractory marginal zone lymphoma a new treatment option and new hope for improving patient outcomes,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
For more information on the FDA approval of zanubrutinib (BRUKINSA), visit the FDA’s website. To learn more about treatment options MZL, visit the Marginal Zone Lymphoma Learning Center.
Learn About: Oral Agents in Lymphoma
Currently, there are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma that can be taken by mouth, either in liquid or tablet/capsule form. Oral agents are just as effective and can have similar side effects as anticancer drugs that are given intravenously.
